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Abstract
Background:  β-catenin is a multifunctional protein involved in two apparently independent
processes: cell-cell adhesion and signal transduction. β-catenin is involved in Wnt signaling pathway
that regulates cellular differentiation and proliferation. In this study, we investigated the expression
pattern of β-catenin and cyclin D1 using immunohistochemistry and searched for mutations in exon
3 of the β-catenin gene and Axin gene in esophageal squamous cell carcinoma.
Materials and methods: Samples were obtained from 50 esophageal cancer patients.
Immunohistochemical staining for β-catenin and cyclin D1 was done. Mutational analyses of the
exon3 of the β-catenin gene and Axin gene were performed on tumors with nuclear β-catenin
expression.
Results:  Four (8%) esophageal cancer tissues showed high nuclear β-catenin staining.
Overexpression of cyclin D1 was observed in 27 out of 50 (54%) patients. All four cases that
showed nuclear β-catenin staining overexpressed cyclin D1. No relationship was observed
between the expression pattern of β-catenin and cyclin D1 and age, sex, tumor size, stage,
differentiation grade, lymph node metastasis, response to chemotherapy, or survival. No
mutational change was found in β-catenin exon 3 in the four cases with nuclear β-catenin staining.
Sequencing analysis of the Axin cDNA revealed only a splicing variant (108 bp deletion, position
2302–2409) which was present in the paired normal mucosa.
Conclusion:  A fraction of esophageal squamous cell carcinomas have abnormal nuclear
accumulation of β-catenin accompanied with increased cyclin D1 expression. Mutations in β-
catenin or axin genes are not responsible for this abnormal localization of β-catenin.
Background
β-catenin is a multifunctional protein involved in two
apparently independent processes: cell-cell adhesion and
signal transduction. β-catenin binds to both the cytoplas-
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mic domain of cadherin and the amino-terminal domain
of β-catenin and mediates cell adhesion. In addition to its
function in cell-cell adhesion, β-catenin plays an impor-
tant role in signal transduction; it is involved in the Wnt
signaling pathway that regulates cellular differentiation
and proliferation [1].
The level of free β-catenin is low in normal cells, since the
protein is sequestered in a complex, which includes the
adenomatous polyposis coli (APC) protein, a serine thre-
onine glycogen kinase (GSK-3β) and conductin or Axin,
leading to degradation of β-catenin by proteasome. The
binding of β-catenin by APC requires phosphorylation of
β-catenin by GSK-3β on 3 serine and 1 threonine residues,
all of which are encoded by exon 3 of the β-catenin gene
[2-4].
In colorectal cancers, mutations of APC or β-catenin result
in stabilization of β-catenin and a significant accumula-
tion of this protein within the cytoplasm [5]. Further-
more, increased β-catenin may translocate to the nuclei
and could serve as a transcriptional factor by binding to
the T-cell factor/lymphoid enhancing factor (Tcf-Lef) fam-
ily [5], leading to transcription of specific genes stimulat-
ing tumor formation, such as cyclin-D1, c-myc, c-jun, fra-1,
uPAR, ZO-1, MMP7, NBL4, DRCTNNB1A, MCP-3 [6-12].
However, the precise regulatory mechanisms remain to be
resolved. Mutations, including large interstitial deletions
involving exon 3 of the β-catenin gene, have also been
found in several other tumors [5,13,14].
Recently, cyclin D1 has been identified as a target of the β-
catenin/T-cell factor/lymphoid enhancer factor complex
[2,15]. Cyclin D1 is expressed in the G1 phase of the cell
cycle, and is thought to play a major role in the control of
the cell cycle and cancer progression. Overexpression of
cyclinD1 has been suggested to contribute to oncogenesis
by disturbing the cell cycle and has been reported to be an
important oncogenic factor in esophageal carcinoma [16].
Recent experiments demonstrated that Axin functions as a
tumor suppressor in hepatocellular carcinoma [17]. The
different domains of Axin possess binding capacity for
APC, GSK-3β,  β-catenin, PP2A, Dishevelled, and Axin
itself [18,19]. As a scaffold protein of this multiprotein
complex, Axin is able to bring β-catenin and GSK-3β into
close proximity, thus facilitating β-catenin phosphoryla-
tion [20,21] and subsequent ubiquitin-mediated degrada-
tion by the proteasome system [22,23].
Esophageal squamous cell carcinoma is an aggressive dis-
ease with a poor prognosis, and the genetic mechanism of
its carcinogenesis remains to be solved. The progression of
this tumor is associated with multiple genetic alterations,
including loss of heterozygosity in chromosomes 3p, 5q,
9p, 9q, 13q, 17p, 17q and 18q, and amplification of epi-
dermal growth factor receptor (EGFR), HER-2, c-myc, and
cyclin D1 [24]. The most frequent genetic alteration in
esophageal squamous cell carcinoma is a point mutation
in the p53 gene (40–60%) that occurs at a relatively early
stage of tumor development [13,25]. However, Wnt signal
pathway in esophageal cancer has not been extensively
studied.
In this paper, we investigated the expression pattern of β-
catenin and cyclin D1 in esophageal squamous cell carci-
noma. We found aberrant localization of β-catenin in a
minor proportion of the tumor and mutation in exon 3 of
the β-catenin gene (CTNNB1) and Axin gene was studied
in these samples.
Materials and methods
Tissue samples
Samples were obtained from 50 esophageal cancer
patients who had undergone operations at the Depart-
ment Surgery II, Nagoya City University Medical School
between 1996 and 2000. They were classified according to
the guideline for the clinical and pathologic studies on
carcinoma of the esophagus [26]. All samples for RT-PCR
were frozen immediately in liquid nitrogen and stored -
80°C until analysis. All the tissues for immunohisto-
chemistry was fixed in formalin and embedded in paraf-
fin.
Immunohistochemical staining for β-catenin and cyclin D1
Immunohistochemical staining was done with anti-β-cat-
enin monoclonal antibody (Transduction Lab.) and anti-
cyclin D1 monoclonal antibody (Oncogene Research
Product). A formalin-fixed paraffin-embedded tissue
block was cut and de-waxed. Each section was treated for
15 min in citric-acid buffer (pH 6.0) with autoclave at
120°C for antigen retrieval, and was immunostained with
the standard indirect ABC technique. Counterstaining was
done with hematoxylin. When more than 20% of the cells
were stained, the staining was scored as positive.
RNA extraction and reverse transcriptional reaction
Total RNA was extracted from the esophageal cancer tis-
sue, and normal esophageal mucosa taken from the
mucosa as far apart from the tumor as possible, using Iso-
gen kit (Nippon gene, Tokyo, Japan). The concentration
of the RNA was adjusted to 200 ng/ml, using spectropho-
tometer. Reverse transcriptional reaction was carried out
at 42°C for 90 min and 95°C for 5 min followed by incu-
bation at 72°C for 15 min, using 1 μg RNA, 0.5 mg
oligo(dTi) primer, Superscript II enzyme (Gibco BRL,
Gaithersburg, MD).World Journal of Surgical Oncology 2007, 5:21 http://www.wjso.com/content/5/1/21
Page 3 of 9
(page number not for citation purposes)
Mutational analyses of the exon3 of the β-catenin and 
axin genes
Polymerase chain reaction (PCR) and direct sequencing
analysis were performed on the four tumors with nuclear
β-catenin expression. Four microliter of cDNA mixture
was subjected to amplification in 80 μl containing 0.8 U
of Taq polymerase, 10×PCR buffer, 25 μM each of dATP,
dCTP, dGTP, dTTP, 25 μM of MgCl2 and 80 pmol each of
5' and 3' primers. PCR conditions for β-catenin were ini-
tial denaturation for 5 min at 95°C, followed by 38 cycles
of denaturation at 94°C for 30 sec, annealing at 56°C for
30 sec, extension at 72°C for 30 sec and a final extension
at 72°C for 5 min. PCR conditions for axin were initial
denaturation for 5 min at 95°C, followed by 38 cycles of
denaturation at 94°C for 60 sec, annealing at 54°C for 60
sec, extension at 72°C for 60 sec and a final extension at
72°C for 5 min. The primer pair used for amplification of
the entire exon 3 of the β-catenin gene and four sets of
primers for axin gene are shown in the Table 1. The iden-
tities of PCR products were analyzed by a 3% agarose gel
electrophoresis. After electrophoresis, the PCR products
were purified from agarose gels using a QIAquick gel
extraction kit (Qiagen, Hilden, Germany) and amplified
with the primer set shown in Table 1. Sequencing was per-
formed with the ABI 3100 DNA Sequencer (Applied Bio-
systems, Foster City, Calif.).
Statistical method
χ-square test was used to analyze the relationship between
the two variables. A p value of less than 0.05 was consid-
ered significant.
Results
Immunohistochemical study for β-catenin
Fifty esophageal cancer tissues and paired normal esopha-
geal mucosa were stained for β-catenin using immunohis-
tochemistry. In all the normal esophageal mucosa, β-
catenin staining was restricted to the plasma membrane.
The intensity of the staining did not vary very much
among individuals. In most of the 50 esophageal cancer
tissues, the β-catenin staining was at the plasma mem-
brane. However, four cases (8%) of esophageal cancer tis-
sue were judged as showing widespread nuclear staining.
And in these cases, β-catenin was not expressed on the
plasma membrane (Fig. 1a). Normal esophageal mucosa
of these cases showed membrane staining of β-catenin,
and did not show nuclear staining (Fig. 1b). 46 other
esophageal cancer samples showed either plasma mem-
brane or cytoplasmic staining or both. No relationship
was observed between β-catenin expression pattern and
age, sex, tumor size, stage, differentiation grade, lymph
node metastasis, response to chemotherapy, or survival
(χ-square test, Table 2).
Immunohistochemical staining for cyclin D1
We then analyzed the expression of cyclin D1, one of the
possible downstream targets of the Wnt signal pathway,
using immunohistochemistry. In all the normal esopha-
geal mucosa, cyclin D1 staining was negative (Fig. 2a).
Overexpression of cyclin D1 was observed in the tumor
nuclei in 27 out of 50 (54%) patients (Fig 2b). All of the
four cases that showed widespread nuclear β-catenin
staining overexpressed cyclin D1. When these 4 cases were
excluded, there was no cooperation between the staining
pattern of β-catenin and cyclin D1 expression. No rela-
tionship was observed between the overexpression of cyc-
lin D1 and age, sex, tumor size, stage, differentiation
grade, lymph node metastasis, response to chemotherapy,
or survival (Table 2).
PCR and direct sequencing analysis of the β-catenin gene
To investigate the mechanism of β-catenin nuclear locali-
zation, we amplified the β-catenin gene by PCR using the
primer pair flanking the entire exon 3. All four cases
showed the single band of 502 bp, and none showed an
aberrant PCR product within the amplified region. Then
we determined the sequence of each band by direct
Table 1: Primer sequences and annealing temperatures for PCR
Primer set Position Annealing temperature
β-catenin exon3
F:GTC TGA GGA GCA GCT TCA GT 77–96 56°C
R:CAT TAG TGG GAT GAG CAG CA 559–578
Axin
F1:GCG GGA CAG ATT GAT TCA CT 28–47 54°C
R1:TCG GCA GGT ATC CAG ATA TG 811–830
F2:TCT GTA GTG ACC AGA GCT CT 771–790 54°C
R2:GAC GAT GGA TCG CCG TCC T 1380–1398
F3:AGT TCG CGG AGG AGC TCA T 1272–1290 54°C
R3:CCT CAA TGA TCC ACT GCA TG 2011–2030
F4:AGG ATG CGG AGA AGA ACC AG 1986–2005 54°C
R4:TCC TGA GTA CGA GGT CAT CT 2770–2789World Journal of Surgical Oncology 2007, 5:21 http://www.wjso.com/content/5/1/21
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Immunohistochemical staining of β-catenin in normal and cancer tissues of the esophagus Figure 1
Immunohistochemical staining of β-catenin in normal and cancer tissues of the esophagus. In this cancer tissues, β-catenin was 
expressed in the nuclei, and was hardly detectable at the plasma membrane (a). In normal esophageal epithelium, β-catenin was 
expressed at the cell membrane (b).World Journal of Surgical Oncology 2007, 5:21 http://www.wjso.com/content/5/1/21
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Table 2: Clinico-pathological characteristics and β-catenin and cyclin-D1 protein expression in 50 patients with esophageal cancer
age/sex follow-up(M) out comea) TN s t a g e l y b) vc) diffd) β-catenine) cyclin D1
16 7 M 3 1 D . O 1 0I 0 0 M M +
24 6 M 2 4 A 1 0I 0 0 M C -
36 8 M 2 6 A 1 1I 1 1 W N + C + M +
45 6 M 1 1 A 1 0I 0 0 M M -
56 8 M 1 8 A 1 0I 0 0 M M +
66 6 M 3 6 D . E 3 0 I I2 1 M C + M -
77 3 F 3 8 A 2 1 I I1 0 W M -
86 9 M 2 D . O 1 2 I I0 0 W M -
96 0 M 3 2 A 1 2 I I0 0 W M +
10 58M 16 D.E 1 1 II 1 1 P N+C +
11 79F 30 D.E 3 0 III 1 1 W N+C +
12 69M 8 D.E 3 2 III 1 0 M C+M -
13 58M 12 D.E 3 1 III 1 1 P M +
14 66M 11 D.E 3 1 III 1 1 M C -
15 66F 39 D.E 3 2 III 1 1 P C -
16 54F 16 D.E 3 3 III 1 0 W C+M -
17 52F 15 D.E 3 2 III 2 1 W M +
18 68M 12 D.E 3 1 III U U n.a. M +
19 68M 26 D.E 3 2 III 1 2 W M -
20 68M 12 D.E 3 1 III 2 1 M M +
21 57F 14 D.E 3 2 III 2 2 W M +
22 61F 6 D.E 3 2 III 1 0 W M -
23 63M 28 D.O 3 3 III 3 1 M C +
24 47F 22 A 3 2 III 1 0 W M +
25 50M 29 A 3 2 III 1 1 P C+M +
26 68M 9 D.E 3 2 III 1 1 M M -
27 70F 4 D.E 3 2 III 1 0 W M -
28 56M 18 A 3 2 III 1 0 W M -
29 68M 9 D.E 4 0 III U U U M +
30 68M 15 D.E 3 3 III 2 2 P M -
31 75M 6 D.E 4 3 IV U U W M -
32 51F 9 D.E 4 2 IV 2 2 M M +
33 67M 2 D.E 4 2 IV U U n.a. M -
34 55M 6 D.E 4 4 IV U U M M -
35 51M 2 D.E 2 4 IV 0 0 M M +
36 69M 8 D.E 4 3 IV U U W C +
37 62M 7 D.E 4 2 IV 1 1 W M -
38 45M 8 D.E 4 3 IV 1 0 W M +
39 46M 3 D.E 4 4 IV 2 1 M M +
40 52M 14 D.E 3 4 IV 1 1 M C +
41 72M 5 D.E 3 4 IV 2 2 M M -
42 53M 13 D.E 4 2 IV 1 0 M M +
43 76M 11 D.E 4 3 IV 1 1 M M +
44 64M 6 D.O 4 2 IV 1 1 M M -
45 51M 6 D.E 4 4 IV U U W M -
46 58M 22 A 4 3 IV U U M C+M -
47 69M 2 D.E 3 4 IV 2 1 W C +
48 57M 13 D.E 4 2 IV 2 2 M M -
49 72M 14 D.E 4 1 IV 1 1 W C -
50 60M 18 A 4 4 IV 2 1 M N+C +
All the samples except cases 18 (unknown) and 33 (adenosquamous carcinoma) were squamous cell carcinomas.
a) D.O; dead with other disease, A; alive D.E; dead with esophageal cancer
b) ly; grade of lymphatic invasion, U; unknown c) v; grade of venous invasion, U; unknown
d) differentiation, W; well differentiated, M; moderately differentiated, P; poorly differentiated, U; unknown, n.a.; not applicable
e) localization by immunostaining, M; membrane, C; cytoplasmic N; nuclear stainingWorld Journal of Surgical Oncology 2007, 5:21 http://www.wjso.com/content/5/1/21
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Immunohistochemical staining of cyclin D1 expression in normal and cancer tissues of the esophagus Figure 2
Immunohistochemical staining of cyclin D1 expression in normal and cancer tissues of the esophagus. In all normal esophageal 
mucosa, cyclin D1 staining was negative (a). In some cancer tissues, cyclin D1 was expressed at the nuclei (b).World Journal of Surgical Oncology 2007, 5:21 http://www.wjso.com/content/5/1/21
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sequencing. No mutational change was found in any of
these cases (data not shown).
PCR and direct sequencing analysis of the Axin gene
We then searched for mutational changes in the Axin
gene. Axin gene mutation may have caused the abnormal
distribution of β-catenin. We examined the Axin cDNA in
four cases showing nuclear localization of β-catenin pro-
tein. Sequencing analysis of the Axin cDNA revealed a
splicing variant (108 bp deletion, position 2302–2409)
and a normal cDNA in two of the cases tested. We
sequenced the cDNA from the normal mucosa in these
cases, and the same variant was found. This deletion
affected the whole exon 9 (Fig. 3). Thus neither β-catenin
exon 3 nor Axin gene mutation was responsible for the
aberrant localization of β-catenin in the 4 cases.
Discussion
In this paper, we searched for changes in some of the pro-
teins and genes involved in the Wnt signaling pathway in
esophageal cancer. We identified abnormal nuclear accu-
mulation of β-catenin protein in 4 (8%) out of the 50
esophageal cancer samples. The aberrant location of this
protein was probably function suggested by the increased
expression of cyclin D1 in all 4 of these cases. However,
we were unable to find any genetic alterations responsible
for this aberrant β-catenin distribution.
Ninomiya et al. have reported that overexpression of β-
catenin was observed in 3 of 22 cases studied (13.6%).
Although no mutation of the β-catenin gene was
observed, the common silent mutation of the APC gene
was found in all the cases [27]. De Castro et al. have
reported that 18% cases of the esophageal squamous cell
carcinoma showed overexpression of β-catenin in the
cytoplasm and nuclei of tumor cells. They found no
genetic alteration of the β-catenin gene [13]. We observed
nuclear expression of β-catenin in 4 cases (8%). This is a
frequency similar to those reported by other researchers.
No mutational change in the β-catenin gene was found in
any of the cases we studied, as reported by others [13].
In esophageal adenocarcinomas, Krishnadath et al.
observed a correlation between reduced expression of β-
catenin and poor prognosis [28]. Furthermore, in esopha-
geal adenocarcinomas, the nucleus was stained in some
tumors by β-catenin immunostaining. Lin et al. have also
reported immunohistochemical data on β-catenin in
esophageal cancer but did not find correlation with malig-
nant behavior of the tumor [29]. In another study β-cat-
enin and cyclin D1 expression was correlated with
survival of esophageal cancer patients [30]. In other series
of esophageal cancers, no mutation in the mutation clus-
ter region of APC and exon3 of β-catenin genes was
detected [7].
It has been reported that immunohistochemical examina-
tion of cyclin D1 expression may provide important prog-
nostic information for esophageal cancer [31]. Takeuchi et
al. have reported that the overexpression of cyclin D1 may
be a useful prognostic indicator in patients with squa-
mous cell carcinomas of the esophagus [32]. And Zhai et
al. have reported that overexpression of cyclin D1 was
highly associated with nuclear accumulation of β-catenin
in ovarian endometrioid adenocarcinomas [33]. In our
studies, no relationship was observed between cyclin D1
expression pattern and clinicopathological features. In
accordance with the report by Zhai et al. all four cases in
our study showing nuclear localization of β-catenin pro-
tein overexpressed cyclin D1.
A number of studies have shown that Axin is critical for
mediating the down regulation of β-catenin [34,35]. One
recent publication reported reduced axin repression in
ESCC [36]. We looked for Axin gene mutations in esopha-
geal squamous cell carcinoma, but found only a splicing
variant.
In conclusion, the nuclear localization of β-catenin occurs
in a fraction of esophageal carcinomas. All the cases show-
ing nuclear localization of β-catenin protein overex-
pressed cyclin D1 which may have contributed to the
oncogenesis of the esophageal carcinoma. The abnormal
Genetic alterations of the Axin gene in esophageal squamous cell carcinoma Figure 3
Genetic alterations of the Axin gene in esophageal squamous cell carcinoma. Splicing variant is indicated by two-headed 
arrows.World Journal of Surgical Oncology 2007, 5:21 http://www.wjso.com/content/5/1/21
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localization of β-catenin apparently did not result from
the genetic alterations of either the β-catenin or Axin gene.
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